Simon Ville

Dr. Simon Ville

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Kidney International
Verified
Journal Article
Closed access
SVSimon Ville
Simon Ville
SBSabine Le Bot
Sabine Le Bot
ACAgnès Chapelet-Debout
Agnès Chapelet-Debout
GBGilles Blancho
Gilles Blancho
VFVéronique Fremeaux-Bacchi
Véronique Fremeaux-Bacchi
FFFadi Fakhouri
Fadi Fakhouri

1 August 2021 in Kidney International
Verified
Journal Article
Closed access
DKDelphine Kervella
Delphine Kervella
LJLola Jacquemont
Lola Jacquemont
ACAgnès Chapelet-Debout
Agnès Chapelet-Debout
CDClément Deltombe
Clément Deltombe
SVSimon Ville
Simon Ville

5 May 2020 in Transplant International
Verified
Journal Article
Closed access
EBElodie Bailly
Elodie Bailly
SVSimon Ville
Simon Ville
GBGilles Blancho
Gilles Blancho
EMEmmanuel Morelon
Emmanuel Morelon
JBJamal Bamoulid
Jamal Bamoulid
MBMatthias Büchler
Matthias Büchler
The treatment of active antibody-mediated rejection (ABMR) is still a matter of debate, the place of rituximab remaining controversial. The French multicenter double-blind RITUX-ERAH study included 38 patients with ABMR in the first year of renal transplantation. All patients received plasma exchanges, intravenous immunoglobulins, and corticosteroids and were randomly assigned rituximab or placebo infusion at day 5. Additional rituximab infusions were allowed. In the intention-to-treat analysis, 12-month graft survival and renal function were not different between the rituximab and placebo groups. Long-term data are needed to conclude. Evaluation of the 7-year outcomes of the RITUX-ERAH study patients according to the rituximab or placebo treatment received. Eleven patients received placebo and 27 at least one infusion of rituximab. Seven years after ABMR, death-censored kidney allograft survival and renal function were not different between the groups. The evolution of anti-HLA sensitization was similar. There was no statistically significant difference in the incidence of infectious or neoplastic complications, but to be noted, seven cancers developed in six patients treated with rituximab (mean period of 44 months post-ABMR). In this cohort, there was no benefit 7 years after ABMR of rituximab in addition to plasma exchanges, intravenous immunoglobulins, and steroids.

23 October 2017 in Transplant International
Verified
Journal Article
Closed access
PDF file
SVSimon Ville
Simon Ville
BIBerthe-Marie Imbert-Marcille
Berthe-Marie Imbert-Marcille
MCMarianne Coste-Burel
Marianne Coste-Burel
CGClaire Garandeau
Claire Garandeau
AMAurélie Meurette
Aurélie Meurette
JDJacques Dantal
Jacques Dantal
Post‐transplantation lymphoproliferative disorder (PTLD) pathogenesis is related to EBV infection. Mismatch with the donor (EBV D+/R−) is the main risk factor for both early PTLD (1 year). In these at‐risk patients, the role of antiviral prophylaxis for preventing PTLD remains controversial. We analyzed the impact of antiviral drugs given to prevent CMV disease in a monocentric retrospective cohort of 73 adult kidney or kidney–pancreas EBV‐seronegative recipients, transplanted between 01/01/2000 and 01/01/2016. Thirty‐seven (50.7%, prophylaxis group) received (val‐)aciclovir or (val‐)ganciclovir for 3–6 months and 36 (49.3%, no‐prophylaxis group) received no‐prophylaxis. Mean follow‐up was 69 ± 7.2 months in the prophylaxis group and 91 ± 10.3 months in the no‐prophylaxis group. Monitoring of EBV PCR revealed that prophylaxis delayed primary infection at 100 days (43% vs. 84%, P = 0.02). Early PTLD incidence was not different between groups (4/37 vs. 4/36, P = 0.99). Concerning late events, EBV‐related neoplasia incidence was significantly lower in treated patients among whom no cases were observed, while in the no‐prophylaxis group 6 cases were reported (P = 0.02). Despite a weak level of evidence our study suggests that antiviral prophylaxis could prevent late onset PTLD.

5 February 2020 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
DCDiego Cantarovich
Diego Cantarovich
DKDelphine Kervella
Delphine Kervella
GKGeorges Karam
Georges Karam
JDJacques Dantal
Jacques Dantal
GBGilles Blancho
Gilles Blancho
MHMaryvonne Hourmant
Maryvonne Hourmant
Tacrolimus, the cornerstone immunosuppression after simultaneous pancreas and kidney transplantation, may exert nephrotoxic and diabetogenic effects. We therefore prospectively compared in an open‐label, randomised, monocentric, 5‐year follow‐up study, a tacrolimus‐ and a sirolimus‐based immunosuppressive regimen. Randomisation using the block method allowing a blind allocation was done at the time of surgery. All patients received anti‐thymocyte globulin and maintenance therapy with tacrolimus, mycophenolate mofetil and steroids. At month 3, tacrolimus was continued or replaced by sirolimus. The primary endpoint was kidney and pancreas graft survival at one and five years. Fifty patients were included in final analysis in each group. At one year, difference for kidney and pancreas graft survival between sirolimus and tacrolimus were 0 % (CI 90 % [‐4.61 %, 4.61 %]) and 6 % (CI 90 % [‐6.32 %, 18.32 %]) respectively. There was neither difference in renal and pancreas graft survival at 5 years. Thirty‐four patients (68 %) in the sirolimus group versus 3 (6 %) in the tacrolimus group needed definitive withdrawal of the study drug. Despite non‐inferiority of sirolimus compared to tacrolimus for kidney and pancreas graft survival, the high rate of sirolimus discontinuation does not favour its use as cornerstone therapy after SPK. NCT00693446

8 December 2021 in Kidney International
Verified
Journal Article
Closed access
CMChristophe Masset
Christophe Masset
SVSimon Ville
Simon Ville
CGClaire Garandeau
Claire Garandeau
FBFlorent Le Borgne
Florent Le Borgne
TLThibaut Letellier
Thibaut Letellier
GBGilles Blancho
Gilles Blancho